DSP-0390

DRUG3 trials

Sponsors

Sumitomo Pharma America, Inc., Washington University School of Medicine

Conditions

Glioblastoma MultiformeGlioma, MalignantHigh Grade GliomaIDH MutationSmall Cell Lung Cancer Extensive StageSmall-cell Lung Cancer

Early Phase 1

Study of DSP-0390 in Patients With Recurrent High-Grade Glioma

Active, not recruitingNCT05023551

Sumitomo Pharma America, Inc.Glioblastoma Multiforme, High Grade Glioma

Start: 2021-09-08End: 2027-10-31Target: 39Updated: 2026-07-29

Window of Opportunity Study of DSP-0390 in Gliomas

RecruitingNCT06636162

Washington University School of MedicineGlioma, Malignant, IDH Mutation

Start: 2025-04-03End: 2027-05-17Target: 20Updated: 2026-05-06

Phase 1

DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer

RecruitingNCT07545954

Washington University School of MedicineSmall-cell Lung Cancer, Small Cell Lung Cancer Extensive Stage

Start: 2026-08-03End: 2030-02-28Target: 20Updated: 2026-08-04

Related Papers

10007-ACT-2 FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

Neuro-Oncology Advances2023-12-01

CTNI-67. FIRST IN HUMAN STUDY OF DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN RECURRENT HIGH-GRADE GLIOMA (HGG): PRELIMINARY RESULTS

Neuro-Oncology2023-11-01

ACT-13 DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: A FIRST-IN-HUMAN, PHASE 1 STUDY

Neuro-Oncology Advances2022-12-01

RTID-03. DSP-0390, AN ORAL EMOPAMIL BINDING PROTEIN (EBP) INHIBITOR, IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA: A FIRST-IN-HUMAN, PHASE 1 STUDY

Neuro-Oncology2022-11-01

DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.

Journal of Clinical Oncology2022-06-013 citations